Table 3 Review of literatures reporting bevacizumab treatment for meningiomas

Putchner MJA, et al. 2010 [4]

1 Anaplstic

60Gy RT

10 mg/kg every 2 weeks

6 months

N/A

1 PR

N/A

hypertension

Goutagny S, et al. 2011 [17]

7 tumors in NF2 pts

none

5 mg/kg Every 2 weeks

15 months

volume

1 tumor: 22 % decrease

N/A

No mention

6 tumors N/C

Lou E, et al. 2012 [5]

5 GI

RT: 12/14

10 mg/kg very 2 weeks

0.5–29.5 months

RANO

0 CR

mPFS: 17.9 months

Tumoral hemorrhage

5 GII

CT: 11/14

1 PR

PFS-6: 85.7 %

G4 intestinal perforation

3 GIII

11 SD

G5 pneumonia/sepsis

1 unk

2 PD

Nayak L, et al. 2012 [18]

6 GII

RT: 15/15

10 mg/kg every 2 weeks

9 doses (1–19 doses)

RANO

0 CR

mPFS: 26 weeks

G1 Intratumoral hemorrhage

9 GIII

CT: 7/15

0 PR

mOS: 15 months

G2 fatigue

15 SD

Nunes FP, et al. 2013 [19]

48 tumors in 15 NF2 pts

5 mg/kg every 2 weeks

Response: 20 % reduction

Tumor: 29 % response

Per-tumor

4 G3 events

Progression: 20 % increase

Patients

PFS-6: 85 %

2 G4 events (wound healing problems)

7 % response

Per-patient

PFS-6: 93 %

Boström JP, et al. 2014 [20]

1 GIII

60Gy RT

5 mg/kg every 2 weeks

2 months

N/A

Stable and growing

N/A

No mention

35Gy SRT